title: Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
abstract: OBJECTIVE
  Adenosine triphosphate cell viability assay (ATP-CVA) was used previously to evaluate chemotherapy in uterine cancer cell lines. In this study, we have performed the ATP-CVA on endometrial cancer patients to study the feasibility of using ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of the cytotoxic drugs.
  
  
  METHODS
  Thirty-three patients with endometrial adenocarcinoma who presented for a staging operation were recruited. Endometrial cancer samples were obtained at the time of operation. In vitro ATP-CVA and chemosensitivity testing was performed using cisplatin, carboplatin, paclitaxel, etoposide, doxorubicin, 4-epidoxorubicin, and topotecan.
  
  
  RESULTS
  Thirty-two of the 33 endometrial cancer samples were evaluable for SF50 (survival fraction at 50% of the peak plasma concentration [PPC]) using ATP-CVA. The median SF50 of carboplatin (0.33) was significantly less than the median SF50 of cisplatin (0.71), topotecan (0.93), paclitaxel (0.68), doxorubicin (1.0), etoposide (0.70), or 4-epidoxorubicin (0.88) (Wilcoxon signed rank test, P <.001).
  
  
  CONCLUSIONS
  This study showed the feasibility of using the ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of cytotoxic drugs.
authors.affiliation: Gynaecological Oncology Division, Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China. tamkfa@netvigator.com
authors.forename: Kar Fai
authors.initials: KF
authors.lastname: Tam
authors.forename: Tong Yow
authors.initials: TY
authors.lastname: Ng
authors.forename: Percy Chi Kit
authors.initials: PC
authors.lastname: Tsang
authors.forename: Chiu Fai
authors.initials: CF
authors.lastname: Li
authors.forename: Hextan Yuen Sheung
authors.initials: HY
authors.lastname: Ngan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000255:Adenosine Triphosphate / Q000032:analysis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D000255:Adenosine Triphosphate